性饮食治疗治疗发作综合征的管理
Meng Wang1,2, Fen Zhao1,2, Lina Sun3
1Epilepsy Center, Children's Hospital Affiliated to Shandong University, Jinan, China.
Frontiers in pediatrics
|November 21, 2024
概括
性饮食疗法 (KDT) 有效地治疗婴儿发作综合征 (IESS),减少发作和改善认知功能. 这种非药理学方法为管理这种具有挑战性的神经疾病提供了一个有希望的替代方案.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 代谢疗法 代谢疗法
背景情况:
- 婴儿发作综合征 (IESS) 在婴儿期呈现出各种原因,往往导致耐火性和智力障碍.
- 目前对IESS的药理治疗有局限性,需要探索替代治疗策略.
- 性饮食疗法 (KDT) 是一种公认的非药物干预方法,用于治疗耐药性.
研究的目的:
- 审查最近的性饮食疗法 (KDT) 治疗婴儿性综合征 (IESS) 的进展.
- 讨论KDT在神经疾病中的各种类型,机制和扩展应用.
- 确定影响KDT有效性的因素,并概述IESS管理的未来研究方向.
主要方法:
- 对IESS的KDT最新科学证据的文献综述.
- 对评估KDT疗效,安全性和耐受性的研究进行分析.
- 探索KDT机制和影响因素.
主要成果:
- 最近的证据支持KDT在治疗IESS中的有效性,安全性和耐受性.
- 在患有IESS的婴儿中,KDT显示了发作频率的显著降低.
- 此外,KDT还显示了改善受影响儿童认知功能和长期预后的潜力.
结论:
- 性饮食疗法是一种有效的非药物治疗药物耐药IESS.
- 肯德基治疗提供了超越控制的好处,包括认知能力的提高.
- 对KDT应用和影响因素的进一步研究是有必要的,以优化神经系统疾病的治疗方法.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
333
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
333
Antiepileptic Drugs: Glutamate Antagonists
283
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
283
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
251
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
251
Antiepileptic Drugs: Sodium Channel Blockers
426
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
426
Antiepileptic Drugs: Calcium Channel Blockers
320
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
320
Antiepileptic Drugs: Potassium Channel Activators
146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
146


